Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b

Antiviral Therapy

Volumn 19, Issue 5, 2014, Pages 479-490

  McPhee, Fiona ^a   Hernandez, Dennis ^a   Zhou, Nannan ^a   Yu, Fei ^a   Ueland, Joseph ^a   Monikowski, Aaron ^a   Chayama, Kazuaki ^b   Toyota, Joji ^c   Izumi, Namiki ^d   Yokosuka, Osamu ^e   Kawada, Norifumi ^f   Osaki, Yukio ^g   Hughes, Eric A ^a   Watanabe, Hideaki ^h   Ishikawa, Hiroki ^h   Kumada, Hiromitsu ⁱ  

^a BRISTOL MYERS SQUIBB   (United States)

^b HIROSHIMA UNIVERSITY   (Japan)

^c Sapporo Kosei General Hospital   (Japan)

^d MUSASHINO RED CROSS HOSPITAL   (Japan)

^e CHIBA UNIVERSITY   (Japan)

^f Osaka Prefecture University   (Japan)

^g OSAKA RED CROSS HOSPITAL   (Japan)

^h Bristol Myers KK   (Japan)

ⁱ TORANOMON HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DACLATASVIR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; BMS-790052; IL28B PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; INTERLEUKIN DERIVATIVE; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; AGED; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; NONHUMAN; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); VIROLOGICAL ESCAPE; VIRUS IMMUNITY; VIRUS LOAD; DRUG COMBINATION; DRUG EFFECTS; FEMALE; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MALE; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; MUTATION; PHENOTYPE; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; INTERFERON-ALPHA; INTERLEUKINS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION; PHENOTYPE; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84924241449     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2729     Document Type: Article

References (20)

1. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55:245-264.
2. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guidelines by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:1433-1444.
3. Poordad F, McCone J, Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
4. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-2416.
5. Vierling JM, Flamm SL, Gordon SC, et al. Efficacy of boceprevir in prior null responders to peginterferon/ribavirin: the PROVIDE study. Hepatology 2011; 54 Suppl 4:796A-797A.
6. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1207-1217.
7. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-2428.
8. Merck & Co. VICTRELIS™ (boceprevir) prescribing information. (Updated February 2013. Accessed 12 June 2013.) Available from http://www.merck.com/product/usa/pi-circulars/v/victrelis/victrelis-pi.pdf.
9. Vertex Pharmaceuticals. INCIVEK™ (telaprevir) prescribing information. (Updated April 2013. Accessed 12 June 2013.) Available from http://pi.vrtx.com/files/uspi-telaprevir.pdf.
10. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465:96-100.
11. Nettles RE, Gao M, Bifano M, et al. Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 2011; 54:1956-1965.
12. Ratziu V, Gadano A, Pol S, et al. Triple therapy with daclatasvir (DCV; BMS-790052), peginterferon alfa-2a and ribavirin in HCV-infected prior null and partial responders: 12-week results of phase 2b COMMAND-2 trial. J Hepatol 2012; 56 Suppl 2:S478-S479.
13. Pol S, Ghalib RH, Rustgi VK, et al. Daclatasvir for previously untreated chronic hepatitis C genotype 1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis 2012; 12:671-677.
14. Fridell RA, Qiu D, Wang C, Valera L, Gao M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 2010; 54:3641-3650.
15. Fridell RA, Wang C, Sun JH, et al. Genotypic and phenotypic analysis of variants resistant to HCV NS5A replication complex inhibitor BMS-790052: in vitro and in vivo correlations. Hepatology 2011; 54:1924-1935.
16. Lok AS, Gardiner D F, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366:216-224.
17. Suzuki F, Chayama K, Kawakami Y, et al. Daclatasvir (BMS-790052), an NS5A replication complex inhibitor, in combination with peginterferon alpha-2b and ribavirin in Japanese treatment-naive and nonresponder patients with chronic HCV genotype 1 infection. 22nd Conference of the Asian Pacific Association for the Study of the Liver. 16-19 February 2012, Taipei, Taiwan. Abstract PP13-003.
18. Izumi N, Asahina Y, Yokosuka O, et al. Combination therapy of treatment-naive and nonresponder patients with HCV genotype 1 infection with daclatasvir (DCV; BMS-790052), an NS5A replication complex inhibitor, in combination with peginterferon alfa-2a and ribavirin. 22nd Conference of the Asian Pacific Association for the Study of the Liver. 16-19 February 2012, Taipei, Taiwan. Abstract PP13-004.
19. Karino Y, Toyota J, Ikeda K, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol 2013; 58:646-654.
20. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335-1374.